Lupin announces partnership with Endoceutics for Intrarosa commercialisation; stock trades flat

Lupin Pharma Canada, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a Canadian biotech company that focuses on women’s health, to commercialise Intrarosa® in Canada.   

Intrarosa® is a flagship product of Endoceutic. It is indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.  

Speaking on the partnership, Lupin commented that the company pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. The product will not expand and strengthen its product portfolio into women’s health in Canada but will also cater to satisfy the unmet medical needs. It is estimated that over 50 per cent of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10 per cent of these women are treated with prescription medicines.   

The product is approved for commercialisation in the US, Europe, UK, Canada, Hong Kong, Israel, United Arab Emirates, Switzerland, and Macau.  

At 1.33 pm today, the stock of Lupin Ltd was trading at Rs 1,035.00, down by 1.39 per cent on BSE.